This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

FDA approves Journavx, a non-opioid medication for moderate to severe acute pain. Learn about its efficacy and side effects.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...

Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...

The Food and Drug Administration on Tuesday approved Journavx, the first drug in a new class of non-opioid pain medications, ...

Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...